<DOC>
	<DOCNO>NCT01784523</DOCNO>
	<brief_summary>In multi-center international study , aim determine effectiveness HCQ primary thrombosis prophylaxis persistently aPL-positive thrombosis-free patient without systemic autoimmune disease .</brief_summary>
	<brief_title>Hydroxychloroquine First Thrombosis Prevention Antiphospholipid Antibody Positive Patients</brief_title>
	<detailed_description>Randomized receive HCQ treatment addition standard regimen . 11 study visit 10 phone visit 5 year .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Antibodies , Antiphospholipid</mesh_term>
	<criteria>Persistent ( least 12 week apart ) aPLpositivity within 12 month prior screen define : aCL IgG/M ( &gt; 40U , mediumtohigh titer , and/or great 99th percentile ) and/or aÎ²2GPI IgG/M ( &gt; 40U , mediumtohigh titer , and/or great 99th percentile ) and/or Positive LA test base International Society Thrombosis &amp; Haematosis Recommendations Selected History thrombosis ( arterial , venous , and/or biopsy proven microthrombosis History Transient Ischemic Attack Confirmed Neurologist SLE Diagnosis base ACR Classification Criteria &gt; 4/11 Other Systemic Autoimmune Diseases diagnose base ACR Classification Criteria Current Hydroxychloroquine another antimalarial treatment ( 3 month ) Current warfarin treatment ( 3 month ) Current heparin therapy ( 3 month ) Current pregnancy History Hydroxychloroquine eye toxicity History Hydroxychloroquine allergy Known glucose6phosphate dehydrogenase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>antiphospholipid autoantibody</keyword>
	<keyword>antiphospholipid positive</keyword>
</DOC>